RINVOQ® is an oral selective and reversible JAK inhibitor indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.1
SKIN CLEARANCE RESULTS: EXPERT OPINION
Dr Kim Papp, Dermatologist and President at Probity Medical Research Waterloo, Ontario, Canada, discusses RINVOQ skin clearance and safety data.
[project # ALL-RNQD-210038]
THE VALUE OF RAPID ITCH RELIEF
Sonja Ständer, Professor of Dermatology and Neurodermatology, Center Chronic Pruritus (KCP) of the University Hospital Münster, Germany, reviews RINVOQ itch reduction efficacy and safety data.
[project # ALL-RNQD-210054]
A WEALTH OF EXPERIENCE WITH RINVOQ ACROSS INDICATIONS
Professor Alan Irvine, Professor of Dermatology from Trinity College School of Medicine in Dublin, Ireland, reviews the clinical trial experience and safety profile of RINVOQ.
[project # ALL-RNQD-210053]
WHICH PATIENTS MAY BENEFIT FROM RINVOQ?
Dr Melinda Gooderham, Medical Director at the SKiN Centre for Dermatology and the Principal Investigator for the SKiN Research Centre in Ontario, Canada, shares her thoughts on which patients may benefit from RINVOQ.
[project # ALL-RNQD-210056]
INITIATING AND MANAGING PATIENTS ON RINVOQ
Dr Melinda Gooderham, Medical Director at the SKiN Centre for Dermatology and the Principal Investigator for the SKiN Research Centre in Ontario, Canada, describes her first-hand experience of initiating and managing patients on RINVOQ.
[project # ALL-RNQD-210055]
PATIENT CASE STUDY 1
[Affiliates to insert case studies approved by local guidance]
PATIENT CASE STUDY 2
[Affiliates to insert case studies approved by local guidance]
PATIENT CASE STUDY 3
[Affiliates to insert case studies approved by local guidance]
FIND OUT MORE ABOUT RINVOQ
REFERENCES
- RINVOQ® (upadacitinib) Summary of Product Characteristics. AbbVie Deutschland GmbH & Co. KG: June 2022.